Rutgers Scientist Receives Edison Patent Award for Potential Leukemia Therapy

Scott Kachlany, an associate professor in the Rutgers School of Dental Medicine, has been honored by the Research & Development Council of New Jersey for his work leading to new potential treatment for leukemia.

Kachlany received the Edison Patent Award at the Council’s annual awards event Nov. 7 in Jersey City’s Liberty Science Center. He discovered a natural protein that in laboratory tests shows significant anti-leukemia activity. The protein, called leukotoxin, comes from a bacterium that causes oral disease. Through his company, Actinobac Biomed Inc., he developed the drug Leukothera to treat leukemia and lymphoma, and is examining how the drug may be used to fight autoimmune diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis. The company is also looking at the drug’s potential in veterinary medicine.

Kathleen Scotto and Scott Kachlany

“Scott is a scientist in oral biology, so his discovery of a promising therapeutic agent for cancer treatment proves that it’s impossible to predict where the most exciting breakthroughs are going to come from,” said R&D Council Chairwoman Kathleen Scotto, who is vice chancellor for research in Rutgers Biomedical and Health Sciences and professor of pharmacology at the Robert Wood Johnson Medical School. “This exemplifies the excellent research being conducted within RBHS, much of which has the potential for clinical applications and commercialization.”

Rutgers Biomedical and Health Sciences, which was established July 1, is the health care education, research, and clinical division of Rutgers, comprising nine schools and their attendant faculty practices, centers, institutes and clinics; New Jersey’s leading comprehensive cancer care center; and New Jersey's largest behavioral health care network.               11/13/13